louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04163484: Contrast-associated Acute Kidney Injury in Patients With Different Types of Coronary Artery Disease
Official title: Contrast-associated Acute Kidney Injury in Patients With Different Types of Coronary Artery Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Angina, Unstable
Angina, Stable
STEMI - ST Elevation Myocardial Infarction
NSTEMI - Non-ST Segment Elevation MI
Contrast-induced Nephropathy
Acute Kidney Injury
Keywords: coronary artery disease
iodinated contrast media
stable angina
unstable angina
STEMI
NSTEMI
PCI
acute kidney injury
Lead sponsor: I.M. Sechenov First Moscow State Medical University
Sponsor class: OTHER
First posted: 2019-11-14
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Males and females aged 18-80, who have the indication for treatment of CAD with PCI requiring the intra-arterial injection of iodinated contrast-media

Brief summary: The goal of the study is to assess the prevalence of contrast-associated acute kidney injury in patients with stable coronary artery disease, ST-elevation myocardial infarction and unstable angina/NSTEMI, assess the risk factors of contrast-induced acute kidney injury development and the influence of contrast-induced kidney injury on 1-year prognosis.


Eligibility criteria: Inclusion Criteria:

* Males and females aged 18-80
* Stable CAD receiving optimal medical treatment requiring PCI or STEMI or NSTEMI
* Intra-arterial injection of iodinated contrast media
* Informed consent

Exclusion Criteria:

* Age less than 18
* Pregnancy, lactation
* Refuse to sign the informed consent
* Contraindications for PCI
* Other conditions affecting prognosis (oncology, liver failure etc)
* CKD stage 4-5
* Patients receiving nephrotoxic drugs

Primary outcomes:
measure: Contrast associated acute kidney injury
timeFrame: 48-72 hours
Secondary outcomes:
measure: Overall mortality
timeFrame: 1 year
measure: Cardiovascular mortality
timeFrame: 1 year
measure: Myocardial infarction
timeFrame: 1 year
measure: Stroke
timeFrame: 1 year
measure: Repeat revascularization
timeFrame: 1 year
measure: Repeat hospitalisation
timeFrame: 1 year
measure: Acute decompensation of heart failure
timeFrame: 1 year
measure: Chronic kidney disease progression
timeFrame: 1 year
measure: New-onset dialysis
timeFrame: 1 year
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: Sechenov University
Study officials:
affiliation: I. M. Sechenov First Moscow State Medical University (Sechenov University)
name: Olga Mironova, MD PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04081584: Trans-abdominal Fetal Pulse Oximetry: Tissue Light Scattering
Official title: Trans-abdominal Fetal Pulse Oximetry: Tissue Light Scattering
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Fetal Distress
Lead sponsor: Raydiant Oximetry, Inc.
Sponsor class: INDUSTRY
First posted: 2019-09-09
Enrollment: 4
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with singleton pregnancies of 36 weeks gestation or more undergoing c-section.

Brief summary: This study is being conducted to study light scattering properties of maternal-fetal tissue.

Detailed description: The ISS customized commercial frequency domain oximeter is used to obtain light scattering information from the maternal abdomen for 10-20 minutes preoperatively and postoperatively in subjects who are having a scheduled C-section.

Eligibility criteria: Inclusion Criteria:

1. Pregnant women with singleton pregnancies, vertex or breech presentation, scheduled for non-emergent cesarean delivery, including cesarean delivery for failure to progress with reassuring electronic fetal heart rate tracing
2. Age greater than or equal to 18 years of age.
3. Healthy women at equal to or greater than 36 weeks gestation undergoing non-emergency cesarean delivery
4. Spinal or epidural anesthesia

Exclusion Criteria:

1. Emergency cesarian delivery
2. Non-reassuring fetal heart rate tracing
3. Less than 18 years of age
4. Multiple gestation (twins, triplets)
5. Presentation other than vertex or breech
6. Less than 36 weeks of gestation
7. General anesthesia

Primary outcomes:
measure: Optical signal from maternal and fetal tissues
timeFrame: Peri-operative
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Tufts Medical Center
state: Massachusetts
Study officials:
References:
Clinical trial NCT01196884: Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Official title: IMMUNE-GENETIC ASSESSMENT OF PRIMARY ITP IN ADULT
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thrombocytopenia
Keywords: Patients with primary Immune Thrombocytopenia (ITP)
Lead sponsor: Azienda Sanitaria-Universitaria Integrata di Udine
Sponsor class: OTHER
First posted: 2010-09-09
Enrollment: 190
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: Primary ITP has wide heterogenous biology, presentation and response to therapy.

The immune-genetic assessment of ITP may help to identify differences among patients with ITP and optimize the therapeutic choice.


Eligibility criteria: Inclusion Criteria:

* Adult patients with primary ITP

Exclusion Criteria:

* Secondary ITP

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Istituto di Ematologia L. & A. Seragnoli
city: Cagliari
country: Italy
facility: Department of Hematology and Bone Marrow Transplantation Unit, Oncology Center Armando Businco
city: Firenze
country: Italy
facility: UF Ematologia, Policlinico di Careggi
city: Milano
country: Italy
facility: U.O. Ematologia 2, IRCCS Cà Granda Ospedale Maggiore Policlinico
city: Milano
country: Italy
facility: Department of Oncology/Haematology, Niguarda Ca'Granda Hospital
city: Novara
country: Italy
facility: Clinica Ematologica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi del Piemonte Orientale "Amedeo Avogadro
city: Novara
country: Italy
facility: Istituto di Immunologia, Dipartimento di Scienze Mediche dell'Università degli Studi del Piemonte Orientale "Amedeo Avogadro"
city: Padova
country: Italy
facility: Department of Medical and Surgical Sciences, University of Padova
city: Ravenna
country: Italy
facility: Oncology-Hematology Department, "S. Maria delle Croci" Hospital
city: Roma
country: Italy
facility: Institute of Hematology, Catholic University,
city: Treviso
country: Italy
facility: Ematologia, Ospedale Ca' Foncello
city: Udine
country: Italy
facility: Clinica Ematologica AOUD S. Maria Misericordia
city: Vicenza
country: Italy
facility: Ematologia, San Bortolo Hospital
Study officials:
References:
Clinical trial NCT00744484: A 12 Week Physical Training Programme for Patients With Chronic Obstructive Pulmonary Disease
Official title: A 12 Week Physical Training Programme for Patients With Chronic Obstructive Pulmonary Disease (COPD)-a Comparison of Water Based and Land Based Group Training
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Chronic Obstructive Pulmonary Disease
COPD
Physical group training
Water exercise
Cardiorespiratory fitness
Functional exercise capacity
Health related quality of life
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Helse Nord-Trøndelag HF
name: Nord-Trøndelag University College
First posted: 2008-09-01
Enrollment: 22
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether water based or land based group training is more effective for people with COPD.

Detailed description: COPD is a more common diagnosis today compared to 20 years ago, and the group is growing fast. The suffering caused by COPD and the financial cost to society is on the increasing. The principal causes of COPD are smoking and inactivity. So far it is poorly understood wich form of exercise is the most effective in training this condition.

Eligibility criteria: Inclusion Criteria:

* COPD GOLD II
* Not taking part in physical activity during the last year

Exclusion Criteria:

* COPD GOLD I, III, IV
* Pain in the legs that make activity difficult

Primary outcomes:
measure: VO2 peak
timeFrame: 12 weeks
Secondary outcomes:
measure: Health related quality of life
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Levanger
country: Norway
facility: Levanger Hosp
state: Nord-Trøndelag
Study officials:
affiliation: Hospital of Levanger / NTNU ISB
name: Thor Naustdal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02827084: Effects of Kinesio Taping in Patellofemoral Pain
Official title: Effects of Kinesio Taping in Painful and Neuromuscular Performance of Patients With Patellofemoral Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Patellofemoral Pain Syndrome
Keywords: electromyography
torque
quadriceps muscle
Lead sponsor: Universidade Federal do Rio Grande do Norte
Sponsor class: OTHER
First posted: 2016-07-11
Enrollment: 54
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aims to analyze the immediate effects and 72 hours after application of the Kinesio Taping (KT) in the electromyographic activity of the vastus medialis oblique (VMO) and vastus lateralis (VL), the isokinetic performance of the quadriceps and referred pain of subjects with PFPS. The volunteers will be randomly assigned to one of the three groups and perform one of the protocols: control - remain at rest; KT - application of Kinesio Taping with tension in the VMO region; placebo - application of Kinesio Taping without tension, in the same region. All volunteers will be submitted to the evaluation of pain intensity, the electromyographic activity of the VMO and VL and dynamometric parameters in 3 times: before the application of KT, immediately after the application of KT and after 72h of application. Average effect estimates (differences between groups) for all variables will be calculated using the mixed model ANOVA with a significance level of 5% (p ≤ 0.05).


Eligibility criteria: Inclusion Criteria:

* Female between 18 and 35 years;
* BMI below 30;
* Clinical diagnosis- previous pain or retropatellar in at least two of the following functional activities: stay for a long time sitting, up or down stairs, run, kneel, crouch, jump;
* Onset of symptoms insidiously and nontraumatic;
* Pain intensity 3 or more on EVA;
* Presence of pain for at least 1 month;

Exclusion Criteria:

* Be performing currently physiotherapy;
* It present surgery, trauma or musculoskeletal system of the lower limb injury within 6 months;
* There have other pathologies associated with the knee joint;
* Does not run the tests properly;
* Does not attend all assessments.

Primary outcomes:
measure: Onset of Electromyographic
timeFrame: Change from baseline in electromyographic at one hour and three days
Secondary outcomes:
Other outcomes:
Locations:
city: Natal
country: Brazil
facility: Federal University of Rio Grande do Norte
state: RN
Study officials:
affiliation: Universidade Federal do Rio Grande do Norte
name: Jamilson S Brasileiro, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04806984: Improving Gap Closure Rates Using a Predictive Model
Official title: Improving Gap Closure Rates Using a Predictive Model
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Communication
Appointments and Schedules
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2021-03-19
Enrollment: 34896
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in the NYU Langone network

Brief summary: NYU Langone Health outreaches to patients to remind them to schedule their appointments by phone or MyChart message.The proposed study will test different outreach methods using a predictive risk model. The goal is to increase gap closure rate by the end of the year.


Eligibility criteria: Inclusion Criteria:

* Patients in the NYU Langone network who are due for gaps in care.

Exclusion Criteria:

* Patients in the NYU Langone network are not due for gaps in care.

Primary outcomes:
measure: Gap closure rate
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: Leora Horwitz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05601284: Psychological Intervention for Misophonia
Official title: Psychological Intervention for Misophonia
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Misophonia
Lead sponsor: Utah State University
Sponsor class: OTHER
First posted: 2022-11-01
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators are proposing to test Acceptance and Commitment Therapy (ACT)+ traditional audiological behavioral intervention as an integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Participants will be 60 adults with misophonia and will be randomly assigned to receive 12 sessions of ACT+behavioral intervention or receive 12 weeks of progressive relaxation training+psychoeducation (PRT; a commonly used active control condition) after undergoing a comprehensive psychological and audiological evaluation.

Detailed description: Acceptance and commitment therapy (ACT) is a promising psychotherapy for supporting traditional behavioral methods for treating misophonia, but has not been previously tested. ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes.

This study will help determine if ACT+behavioral intervention is a feasible and acceptable treatment for misophonia, help clarify active psychological mechanisms of misophonia, and determine whether or not this combination of services can effectively help individuals diagnosed with misophonia.

Eligibility criteria: Inclusion Criteria:

* Individuals seeking treatment for misophonia.
* Meet clinical cut-off for misphonia (minimum score of five on the Misophonia Questionnaire).
* Stable on psychotropic medication for at least 30 days.
* English speaking.

Exclusion Criteria:

* Presence of psychological and/or neurological impairments that would preclude someone from participating in the study or exceed misophonia as the primary presenting problem (e.g. active self-harm or need for treatment for psychosis).

Primary outcomes:
measure: Misophonia Questionnaire
timeFrame: 9-12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Logan
country: United States
facility: Utah State University
state: Utah
Study officials:
affiliation: Utah State University
name: Michael Twohig, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00741884: A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation
Official title: A Phase 2, Seven Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group Study To Evaluate The Safety And Efficacy Of Three Doses Of A Controlled Release Formulation Of Varenicline For Smoking Cessation
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Smoking Cessation
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-08-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety, efficacy, and tolerability of twice daily (BID) administration of three dose strengths (1.2 mg, 1.8 mg, and 2.4 mg) of varenicline controlled release (CR) tablets in adult smokers.


Eligibility criteria: Inclusion Criteria:

* Male or female cigarette smokers between the ages of 18 and 75 years, inclusive, who are motivated to stop smoking.
* Females of non-childbearing potential (surgically sterilized or at least 2 years postmenopausal) who are not nursing may be included.
* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion Criteria:

* Subjects with clinically significant cardiovascular disease in the past 6 months.
* Subjects hospitalized within the past 12 months due to suicidal ideation or suicidal behavior or subjects considered to have serious suicidal ideation or suicidal behavior within the past 12 months.
* Subjects having active suicidal ideation or behavior identified at Screen or Baseline.
* Subjects currently or within the past 12 months requiring treatment for depression. Subjects with current or prior history of panic disorder, anxiety disorder, hostility or aggression disorder, perceptual/thinking disturbances, psychosis, or bipolar disorder.

Primary outcomes:
measure: Continuous abstinence from smoking for weeks 4-7, carbon monoxide confirmed
timeFrame: 7 weeks
Secondary outcomes:
measure: 7- day point prevalence of non-smoking at week 7
timeFrame: 7 days
measure: Scores on the Minnesota Nicotine Withdrawal Scale subscales
timeFrame: 7 weeks
measure: Scores on the Modified Cigarette Evaluation Questionaire subscales
timeFrame: 7 weeks
measure: PK analysis
timeFrame: 7 weeks
measure: Safety Assessments: adverse events, C-SSRs, vital signs, body weight
timeFrame: 7 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT03694184: A Pilot Study of the Effect of Individualized Clinical Management Among Parent/Child Dyads on Continuity of Care and Interaction
Official title: A Pilot Study of the Effect of Individualized Clinical Management Among Parent/Child Dyads on Continuity of Care and Interaction. Phase 1 : Retrospective Evaluation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Child Psychiatry
Psychodynamic Therapy
Continuity/Discontinuity
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2018-10-03
Enrollment: 50
Sex: ALL
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Family having with a first consultation request submitted from 2015 Children aged \< 10 years old at the time of the first consultation

Brief summary: this project aims to collect retrospective data on the conitinuity/disconitnuity rate for child care in the child psychiatry unit of the université hospital of Besançon, France.


Eligibility criteria: Inclusion Criteria:

* Family having with a first consultation request submitted from 2015
* Children aged \< 10 years old at the time of the first consultation

Primary outcomes:
measure: rate of contuinity/discontinuity of child care
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de Besançon
Study officials:
affiliation: CHU de Besançon
name: Vulliez Lauriane, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03311984: Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
Official title: Evaluation of Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Critically Ill
Anti-Xa
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2017-10-17
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult Critically ill patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis.

Brief summary: Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threatening embolism. The purpose of this study is to evaluate the anti-Xa levels of different dosing regimens of LMWH in critically ill patients in China.


Eligibility criteria: Inclusion Criteria:

* Adult Critically ill patients

Exclusion Criteria:

* Contraindication to use of LMWH. Intracranial bleeding/stroke, hematoma or bleeding disorder. Use Heparin anticoagulant therapy

Primary outcomes:
measure: Anti-Xa Levels
timeFrame: six months
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Changde Wu
state: Jiangsu
Study officials:
References:
Clinical trial NCT02854384: Mobile Phone Radiation and Brain Rhythm in Epileptic Patients
Official title: Mobile Phone Radiation and Brain Rhythm in Epileptic Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epilepsy
Keywords: Epilepsy
Mobile phone
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2016-08-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study included 30 epileptic patients and 30 healthy volunteers, males and females whose age above 18 years.

Brief summary: This work is intended to assess the effect of -30 minutes- exposure to mobile-phone on the functions of the central nervous system (CNS) in epileptic patients.

Detailed description: This work shows the effect of the 30 minutes mobile waves' radiation over the normal person brain activity (EEG) and cognition (P300) together with the effect over the unstable brain of the epileptic patients. Exposure to mobile-phone radiation has been reported to increase the spectral power of electroencephalograms (EEGs), particularly in the alpha band, during both the waking and sleeping states. The tendency toward electrical instability of the neural networks of epileptic patients suggests that these individuals may be especially sensitive to electromagnetic fields espcially mobile-phone radiation (MPR). The short-term effects of exposure to electromagnetic (EM) fields on a number of cognitive variables such as memory, attention and speed of decision-making could be assedsed by P 300 latency and amplitude.

Eligibility criteria: Inclusion Criteria:

* Both sexes
* Above 18 years
* Epileptic patients (regardless of whether symptomatic, idiopathic, focal or generalized)

Exclusion Criteria:

* Age less than 18 years
* Chronic medical condition
* Epileptic fit in the last 48 hours

Primary outcomes:
measure: Digital Electroencephalography (EEG) examination
timeFrame: one day
measure: P300 test
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: